Aricept to face competition from new Alzheimer’s patch
Aricept, the most widely used drug to treat Alzheimer’s disease is to face some stiff competition from a new player in the market.
Exelon, developed by pharmaceutical company Novartis is now available in a patch form which is claimed to offer various benefits over traditional pills such as Aricept.
The patch acts as a slow release medication, and side effects most commonly associated with Aricept such as nausea and vomiting were still possible but minimised with a skin patch approach.
Experts were quick to point out that whilst the new Exelon patch would help a lot of sufferers of Alzheimer’s, it was still not a cure for the degenerative brain disorder which affects over 26 million people worldwide.
The main prescription drugs on the market to treat Alzheimer’s at the moment are Aricept, Exelon, Razadyne.
